NCT03052751 - Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

May 31, 2018

Study Completion Date

August 6, 2018

Conditions

Myasthenia Gravis

Interventions

DRUG

UCB7665

UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)

OTHER

Placebo

Placebo will be administered in period 1 of dosage regimen 2.

Trial Locations (20)

30912

Mg0002 707, Augusta

33136

Mg0002 713, Miami

33612

Mg0002 708, Tampa

43210

Mg0002 704, Columbus

90033

Mg0002 712, Los Angeles

92868

Mg0002 701, Orange

Unknown

Mg0002 102, Brussels

Mg0002 103, Ghent

Mg0002 101, Leuven

Mg0002 203, London

Mg0002 202, Montreal

Mg0002 201, Toronto

Mg0002 302, Ostrava-Poruba

Mg0002 401, Aarhus

Mg0002 402, Copenhagen

Mg0002 505, Düsseldorf

Mg0002 502, Gummersbach

Mg0002 501, Jena

Mg0002 601, Barcelona

Mg0002 602, Barcelona

All Listed Sponsors

lead

UCB Biopharma S.P.R.L.

INDUSTRY